NCT04786847View on ClinicalTrials.gov

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 30, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Metastatic Prostate Cancer
Interventions
BIOLOGICAL

177Lu-DOTA-TLX591

TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)

Trial Locations (3)

2290

GenesisCare Newcastle, Newcastle

6009

Diagnostic Nuclear Imaging at Hollywood Private Hospital, Perth

6150

GenesisCare SJOg Medical Centre,Murdoch, Perth

All Listed Sponsors
lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY